Characterization of IL-2-induced Murine Cells Which Exhibit ADCC Activity
Overview
Cell Biology
Authors
Affiliations
The incubation of murine splenocytes in recombinant interleukin 2 (IL-2) gives rise to both lymphokine-activated killer (LAK) cells capable of lysing fresh tumor cells and cells capable of mediating antibody-dependent cellular cytotoxicity (ADCC) in the presence of anti-H2 allosera. A similarity between these two IL-2-induced cell populations was found. The precursors of the cells mediating these activities were shown to be ASGM1 positive, Thy 1 negative, and radiosensitive. Cells taken from the spleen, thymus, and bone marrow were able to mediate ADCC after culture in IL-2. The effector cell was either Thy 1 positive or negative and was less affected by anti-Thy 1 plus C' treatment than cells which mediated LAK activity. In addition ADCC was exhibited in IL-2-cultured splenocytes from various murine strains and correlated with their LAK activity with one exception. While IL-2-cultured C57BL/6 splenocytes exhibited LAK activity similar to that of C3H LAK cells, no ADCC activity could be demonstrated in C57BL/6 cells. Study of the difference in the ability of these two strains to mediate ADCC revealed that IL-2-induced FcR+ cells in C3H thymocytes, but not in C57BL/6 thymocytes. Based on FACS analysis and on the radiosensitivity of the induction of both FcR+ cells and ADCC, it was suggested that IL-2 was expanding a small FcR+ cell population rather than inducing an increase in FcR density on the cell surface. The relationship between the IL-2-induced ADCC mediator and other IL-2-induced cells, as well as ADCC effector cells, and the possible implications of the results for the in vivo therapy of cancer based on ADCC are discussed.
Ramakrishna V, Eisenthal A, Skornick Y, Shinitzky M Cancer Immunol Immunother. 1993; 36(5):293-9.
PMID: 8477415 PMC: 11038729. DOI: 10.1007/BF01741167.
Vuist W, Visseren M, Otsen M, Bos K, Vyth-Dreese F, Figdor C Cancer Immunol Immunother. 1993; 36(3):163-70.
PMID: 8439976 PMC: 11038052. DOI: 10.1007/BF01741087.
Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.
Eisenthal A, Kashtan H, Rabau M, Ramakrishna V, Chaitchik S, Skornick Y Cancer Immunol Immunother. 1993; 36(2):101-7.
PMID: 8425207 PMC: 11038442. DOI: 10.1007/BF01754409.
Eisenthal A, Skornick Y, Merimsky O, Hirsch R, Zakut V, Ron I Cancer Immunol Immunother. 1993; 37(4):233-9.
PMID: 8348562 PMC: 11038831. DOI: 10.1007/BF01518516.
Eisenthal A Cancer Immunol Immunother. 1990; 31(6):342-8.
PMID: 2386979 PMC: 11038655. DOI: 10.1007/BF01741405.